Log in

NASDAQ:AGLEAeglea Bio Therapeutics News Headlines

$4.01
-0.34 (-7.82 %)
(As of 04/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.00
Now: $4.01
$4.29
50-Day Range
$3.51
MA: $6.06
$8.48
52-Week Range
$3.50
Now: $4.01
$9.10
Volume76,525 shs
Average Volume84,439 shs
Market Capitalization$116.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.38

Headlines

Aeglea Bio Therapeutics (NASDAQ AGLE) News Headlines

Source:
DateHeadline
Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Particularly Volatile Share Price?Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Particularly Volatile Share Price?
finance.yahoo.com - March 29 at 5:30 PM
Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Short Interest Up 40.9% in MarchAeglea Bio Therapeutics Inc (NASDAQ:AGLE) Short Interest Up 40.9% in March
www.americanbankingnews.com - March 28 at 2:10 AM
Zacks: Analysts Expect Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) to Announce -$0.66 EPSZacks: Analysts Expect Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) to Announce -$0.66 EPS
www.americanbankingnews.com - March 22 at 4:22 PM
Aeglea BioTherapeutics EPS beats by $0.03Aeglea BioTherapeutics EPS beats by $0.03
seekingalpha.com - February 24 at 1:59 PM
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent MilestonesAeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
finance.yahoo.com - February 24 at 8:58 AM
Should Aeglea BioTherapeutics (NASDAQ:AGLE) Be Disappointed With Their 66% Profit?Should Aeglea BioTherapeutics (NASDAQ:AGLE) Be Disappointed With Their 66% Profit?
finance.yahoo.com - February 13 at 7:08 AM
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
finance.yahoo.com - January 13 at 4:35 PM
Is Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) CEO Salary Justified?Is Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) CEO Salary Justified?
finance.yahoo.com - January 8 at 5:12 PM
Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare ConferenceAeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 8:29 PM
Hedge Funds Are Dumping Aeglea BioTherapeutics, Inc. (AGLE)Hedge Funds Are Dumping Aeglea BioTherapeutics, Inc. (AGLE)
finance.yahoo.com - December 12 at 11:55 PM
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Increased Their HoldingsAeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Increased Their Holdings
finance.yahoo.com - December 3 at 6:50 AM
Aeglea BioTherapeutics EPS misses by $0.12Aeglea BioTherapeutics EPS misses by $0.12
seekingalpha.com - November 13 at 12:47 PM
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate HighlightsAeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
finance.yahoo.com - November 6 at 1:19 PM
Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial OfficerAeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
finance.yahoo.com - November 4 at 1:14 PM
Will Aeglea BioTherapeutics (NASDAQ:AGLE) Spend Its Cash Wisely?Will Aeglea BioTherapeutics (NASDAQ:AGLE) Spend Its Cash Wisely?
finance.yahoo.com - October 10 at 12:13 PM
Aeglea Bio Therapeutics IncAeglea Bio Therapeutics Inc
www.reuters.com - October 2 at 8:43 PM
Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Volatile Share Price?Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Volatile Share Price?
finance.yahoo.com - September 5 at 1:57 PM
Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM SymposiumAeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium
finance.yahoo.com - August 29 at 11:41 AM
Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate HighlightsAeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
www.marketwatch.com - August 6 at 10:26 AM
Aeglea BioTherapeutics EPS misses by $0.07Aeglea BioTherapeutics EPS misses by $0.07
seekingalpha.com - August 6 at 10:26 AM
Aeglea BioTherapeutics: Investment Potential Addressing Unmet NeedAeglea BioTherapeutics: Investment Potential Addressing Unmet Need
seekingalpha.com - July 30 at 9:51 AM
Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 DeficiencyAeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
finance.yahoo.com - July 24 at 8:09 PM
Can We See Significant Institutional Ownership On The Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Share Register?Can We See Significant Institutional Ownership On The Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Share Register?
finance.yahoo.com - July 17 at 6:09 PM
Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $196,535 of SharesAeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $196,535 of Shares
finance.yahoo.com - June 15 at 12:13 AM
Hedge Funds Have Never Been This Bullish On Aeglea BioTherapeutics, Inc. (AGLE)Hedge Funds Have Never Been This Bullish On Aeglea BioTherapeutics, Inc. (AGLE)
finance.yahoo.com - June 12 at 11:25 AM
Aeglea BioTherapeutics (AGLE) Presents At Jefferies 2019 Healthcare Conference - SlideshowAeglea BioTherapeutics (AGLE) Presents At Jefferies 2019 Healthcare Conference - Slideshow
seekingalpha.com - June 7 at 4:34 PM
Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 DeficiencyAeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
finance.yahoo.com - June 3 at 8:45 AM
Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry ConferencesAeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences
finance.yahoo.com - May 30 at 8:54 AM
Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $180,028 of SharesAeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $180,028 of Shares
finance.yahoo.com - May 23 at 8:54 AM
Have Insiders Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares?Have Insiders Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares?
finance.yahoo.com - April 27 at 5:19 PM
Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic DisordersAeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
finance.yahoo.com - April 7 at 11:45 PM
Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic DisordersAeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
finance.yahoo.com - April 1 at 8:58 AM
Aeglea BioTherapeutics to Participate in Upcoming Investor ConferencesAeglea BioTherapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - March 28 at 9:04 AM
Aeglea BioTherapeutics IncAeglea BioTherapeutics Inc
www.bloomberg.com - March 19 at 9:10 AM
Edited Transcript of AGLE earnings conference call or presentation 7-Mar-19 9:30pm GMTEdited Transcript of AGLE earnings conference call or presentation 7-Mar-19 9:30pm GMT
finance.yahoo.com - March 9 at 8:37 AM
Aeglea BioTherapeutics (AGLE) CEO Anthony Quinn on Q4 2018 Results - Earnings Call TranscriptAeglea BioTherapeutics' (AGLE) CEO Anthony Quinn on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 8 at 8:58 AM
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate HighlightsAeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
finance.yahoo.com - March 7 at 6:34 PM
The Aeglea BioTherapeutics Share Price Is Up 11% And Shareholders Are Holding OnThe Aeglea BioTherapeutics Share Price Is Up 11% And Shareholders Are Holding On
finance.yahoo.com - March 6 at 7:02 PM
Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference CallAeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
finance.yahoo.com - February 28 at 8:58 AM
Aeglea aims to raise $60M for treating rare diseasesAeglea aims to raise $60M for treating rare diseases
finance.yahoo.com - February 7 at 6:18 PM
Aeglea Biotherapeutics prices $60M equity offeringAeglea Biotherapeutics prices $60M equity offering
seekingalpha.com - February 6 at 8:59 AM
Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public OfferingAeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering
finance.yahoo.com - February 6 at 8:59 AM
How Much Of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Do Institutions Own?How Much Of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Do Institutions Own?
finance.yahoo.com - January 29 at 5:51 PM
Is Aeglea BioTherapeutics, Inc. (AGLE) A Good Stock To Buy?Is Aeglea BioTherapeutics, Inc. (AGLE) A Good Stock To Buy?
finance.yahoo.com - December 23 at 8:33 AM
What Investors Should Know About Aeglea BioTherapeutics, Inc.’s (NASDAQ:AGLE) Financial StrengthWhat Investors Should Know About Aeglea BioTherapeutics, Inc.’s (NASDAQ:AGLE) Financial Strength
finance.yahoo.com - December 14 at 5:21 PM
This page was last updated on 4/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel